The study was undertaken to examine the association of the insertion-detection (ID) polymorphism of angiotensin-converting enzyme (ACE) gene with the development and progression oJ diabetic nephropathy (DN) and to establish a relationship of different allele types of genetic- polymorphism to the efficiency of microalbuminuria (MAU) diminution in captopril-treated patients with evolving DN. The study of the I/D polymorphism of ACE gene revealed no statistical differences in the distribution of genotypes and alleles in the group of patients with (n = 17) and without (n = 79) DN. However, the significantly higher frequency of D allele was found in patients with end-stage DN (significant nephropathy and uremia) as compared with those of early-stage DN (MAU) (p<0,05). The revealed regularity may suggest that the presence of D allele in the structure of ACE gene is one of the markers of progression of diabetes-induced renal lesion in patients with type I diabetes mellitus One-month captopril therapy in patients with evolving DN (n = l3) causes a statistically significant decrease in MAU. At the same time, there were no significant differences in the group of patients with different allele genotypes of ACE.

An open comparative controlled study of the use of the calcium antagonists nifedipine SR/GITS and amlodipine was conducted in patients with hypertensive disease. The results suggest that both drugs have a high and stable antihypertensive activity during a day: they are sale and produce a positive effect on the life quality in the patients. Therapy in both groups improved the parameters of heart rate variability and daily blood pressure profile, which are important risk factors of the progression of cardiovascular diseases and their mortality. However, it should be noted that there was a more marked antihypertensive effect and a more Significant improvement of heart rate variability parameters in the nifedipine SR/GITS group than in the amlodipine group.

Thirty patients with grades 1-3 arterial hypertension were examine to evaluate in patients with arterial hypertension the effectiveness and safety of treatment in patients with angiotensin-converting enzyme (ACE) inhibitor enalapril and the thiazide-type diuretic chlortalidone and to study the impact of this therapy on the great arteries. This combined therapy could reduce systolic blood pressure (BP) from 166,9 ± 22,8 to 135,7 ± 14,1 mm Hg, diastolic BP from 101,8 ± 22,8 to 135,7 ± 14,1 mm Hg (p < 0,001). Baseline pulse pressure was 68,9 ± 16,2 mm Hg, alter 12-week therapy, it was 50,5 ± 12,2 mm Hg (p < 0,001). Volumetric sphygmography demonstrated a reduction in arterial rigidity. The rate of pulse wave propagation significantly decreased from 14,8 ± 2,0 to l4,l ± 1,9 m/sec. Symmetrical changes were also observed in the rigidity of vessels, as also evidenced by the data of high-resolution ultrasound. The rigidity p-index reduced by almost 2596 - from 35,5 ± 13,3 to 26,8 ± l6,3; p = 0,02.The reduction in the rigidity of common femoral arteries was confirmed by a rise in their elasticity the compliance coefficient clearly tended to increase. Thus, the use of enarenal and oxodoline improved the function of great arteries just within the first 3 months of therapy.

The objective of the study was to examine the effects of noliprel on renal hemodynamics and to establish correlations in the vascular regions of the heart and kidneys. The authors performed a 0-month open randomized study that included 35 patients (9 males and 26 females) aged 40 to 65 years (mean 55.8 ± 7.8 years) who had grades 1 and 2 arterial hypertension (AH). Blood pressure (BP), the rigidity of large arteries, cardiac remodeling, total peripheral vascular resistance, and renal blood flow were monitored during therapy. All studies were performed before and о months alter therapy. Results: The target BP (< 140/90 mm Hg) was achieved in 88.0 % оf the patients by the end of the sixth month. The drug was found to have a positive effect on cardiac remodeling reductions in the thickness of the interventricular septum (by 9.9 %), the relative thickness of the walls (by 4.5 %), the left ventricular myocardial mass index (LVMMI) (by 9.5 %) and an increase in the E/A ratio from (0.8 ± 0.07 to 1.1 ± 0.08 (p < 0.01). Noliprel therapy decreased renal resistance indices (RI) (particularly at the level of the ostium of renal arteries and interlobar renal arteries) - RI reduced by 5.9 and 9.2 respectively ( p < 0.01) and Pi decreased by 2.5 and 9.7 % (p < 0.01), reduced the systolic/diastolic ratio (p < 0,01), and significantly increased renal blood flow velocities. There was a direct relationship of the renal indices of peripheral resistance to the rigidity of large arteries, mean and pulse BP, LVMMI, and total peripheral vascular resistance. Conclusion. The results of the study confirm that there is an early cardiovascular remodeling (primarily damages to the most important target organs the heart and kidneys) in patients with mild and moderate hypertension. Noliprel therapy reduced the peripheral resistance of large and minor vessels, diminished myocardial hypertrophy, and recovered left ventricular diastolic function. Noliprel improves renal blood flow due to diminished peripheral vascular resistance at the level of the ostium of renal arteries, the renal portal and intrarenal vessels, which suggests that the drug has renal protective properties.

The paper evaluates the impact of 26-week therapy with rilmenidine in a dose of 1-2 mg daily and with atenolol in a dose of 50 100 mg daily on life quality parameters determined by the SF-Зб scale in 51 patients with essential hypertension during an open randomized controlled study in parallel groups. Most life quality parameters were found to improve during monotherapy with both drugs. Whereas there was a deterioration in some life quality subspheres (social and emotional) during atenolol therapy, which was not observed in a group of patients receiving rilmenidine where there were minimal adverse reactions that did not require discontinuance of therapy or correction the dose.

105 females who had excess body weight, metabolic disturbances with and without insulin resistance were examined to study the impact of carbohydrate metabolic disturbances and the severity of arterial hypertension on the major parameters of thrombocytovascular link of hemostasis. The results of the study suggest that the degree of insulin resistance determines the magnitude of unfavorable hemostatic shifts to a greater extent than the level of blood pressure, by enhancing hypercoagulation activity in the metabolic syndrome.

The changes m 24-hour blood pressure (BP) monitoring were studied in 63 patients with grade I hypertension concurrent with cervical osteoarthrosis in the treatment with the angiotensin-converting enzyme (ACE) inhibitor enalapril in combination with hydrochlorothiazide. The degenerative and dystrophic process in the cervical pan of the spine was shown to exert a negative effect on the daily BP profile, by increasing the variability and the morning elevation of BP, to keep antihypertensive agents from producing their adequate effect. The hypertensive patients with die vertebral arterial syndrome respond to therapeutic measures worse, which shows it necessary to apply a differential approach to treating this category of patients.